Prevalence of Side Effects, Drug Interaction among Patients Taking Statin in Turaif, Saudi Arabia

Main Article Content

Maria Abdul Ghafoor Raja
Gharam Hamdan Alrawili
Nawaf Al-Otaibi
Muhammad Wahab Amjad

Abstract

Background: Statins perceived to have favorable safety profile. Although many people on statin therapy do well but no drug is without potential for side effects. Awareness about risks as well as benefits of drugs is needed particularly drugs which are used on wide scale like statins because even uncommon side effects can have significant health impact. 

Objectives of the Study: To determine side effects occurrence among Saudi patients taking statins and to evaluate drug-drug interactions in Saudi patients taking statins.

Methodology: Self administered cross sectional study conducted during a period of four months from October 2018 to January 2019 in Turaif general hospital, Saudi Arabia on random sample of 500 Saudi patients out of which 330 participants were included in the study which were taking different types of statins medication using self-administered questionnaire in Arabic language specially designed for the research purpose after obtaining verbal consent and the data analyzed by SPSS program.

Results: A total of 330 patients; 128 (39%) females and 202 (61%) males—participated in the study. The majority 165 (50%) were in the age-group of 50 – 59 years. Simvastatin was the most commonly used statin among study participants 136 (41%) followed by rosuvastatin 114 (35%). Among the participants, there were some patients who take drugs which have drug interactions with statins; there were 64 (19%) take Amlodipine with simvastatin, 13 (4%) and 6 (2%) take esomeprazole and ompeprazole respectively with statins. Only 9 (3%) reported that they were advised by pharmacist to avoid grape fruit. Majority of participants 309 (94%) reported neck pain, difficulty in walking, frequently fatigue after starting on statin. Also majority of participants 320 (97%) suffer from muscle pain after starting statins medications.

Conclusion: The percentage of statin related side effects in this study population is high especially myopathy. Also some patients in this study taking medications that have drug interaction with statins, Counseling to patient regarding statin therapy appear to be insufficient. So, this study indicate that there's a need for more efforts from the physicians and pharmacist to avoid prescribing or dispensing medication that have drug-drug interaction with statins and provide counseling to patients regarding their statin therapy.

Keywords:
Statins, drug-drug interactions, simvastatin, omeprazole, counseling.

Article Details

How to Cite
Raja, M. A. G., Alrawili, G. H., Al-Otaibi, N., & Amjad, M. W. (2020). Prevalence of Side Effects, Drug Interaction among Patients Taking Statin in Turaif, Saudi Arabia. Journal of Pharmaceutical Research International, 32(3), 86-97. https://doi.org/10.9734/jpri/2020/v32i330417
Section
Original Research Article

References

Criqui MH, Golomb BA. Low and lowered cholesterol and total mortality. J Am Coll Cardiol. 2004;44:1009–10.

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group [see comments]. New England Journal of Medicine. 1998;339:1349–57.

Davidson MH. Safety profiles for the HMG-CoA reductase inhibitors: Treatment and trust. Drugs. 2001;61:197–206.

Smith SCJ. Bridging the treatment gap. American Journal of Cardiology 2000;85: 3E–7E.

Bernini F, Poli A, Paoletti R. Safety of HMG-CoA reductase inhibitors: Focus on atorvastatin. Cardiovasc Drugs Ther. 2001; 15:211–8.

Buhaescu I, Izzedine H. Mevalonate pathway: A review of clinical and therapeutical implications. Clin Biochem. 2007;40:575–84.

Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:42530.

Mach F. Statins as immunomodulatory agents. Circulation 2004;109:II15–7.

Keyhani J, Keyhani E. Mevalonic acid as a precursor of the alkyl sidechain of heme a of cytochrome c oxidase in yeast Saccharomyces cerevisiae. FEBS Lett. 1978;93:271–4.

Mol MJ, Stalenhoef AF, Stuyt PM, Hermus AR, Demacker PN, Van TLA. Effects of inhibition of cholesterol synthesis by simvastatin on the production of adrenocortical steroid hormones and ACTH. Clin Endocrinol (Oxf). 1989;31: 679–89.

Hyyppa MT, Kronholm E, Virtanen A, Leino A, Jula A. Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial. Psycho-neuroendocrinology. 2003;28:181–94.

Cimino M, Gelosa P, Gianella A, Nobili E, Tremoli E, Sironi L. Statins: Multiple mechanisms of action in the ischemic brain. Neuroscientist. 2007;13:208–13.

Harris JI, Hibbeln JR, Mackey RH, Muldoon MF. Statin treatment alters serum n-3 and n-6 fatty in hypercholesterolemic patients. Prostaglandins Leukot Essent Fatty Acids. 2004;71:263–9.

Maritz FJ. Efficacy and dangers of statin therapy. Cardiovasc J S Afr. 2002;13:200–3.

Talbert RL. Safety issues with statin therapy. J Am Pharm Assoc (Wash DC), Quiz 488-90. 2006;46:479–88.

Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997;18(Suppl):S137–44.

Mahoney DJ, Parise G, Tarnopolsky MA. Nutritional and exercise-based therapies in the treatment of mitochondrial disease. Curr Opin Clin Nutr Metab Care. 2002; 5:619–29.

Rosenfeldt FL, Pepe S, Linnane A, et al. Coenzyme Q10 protects the aging heart against stress: Studies in rats, human tissues, and patients. Ann N Y Acad Sci. 2002;959:355–9.

Barbiroli B, Frassineti C, Martinelli P, et al. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. Cell Mol Biol (Noisy-le-grand). 1997;43: 741–9.

Davidson MH. Safety profiles for the HMG-CoA reductase inhibitors: Treatment and trust. Drugs. 2001;61:197–206.

Maritz FJ. Efficacy and dangers of statin therapy. Cardiovasc J S Afr. 2002;13: 200–3.

Talbert RL. Safety issues with statin therapy. J Am Pharm Assoc (Wash DC). 2006;46:479–88.

Camelia S, Anca S. Statins: Mechanism of action and effect. J. Cell Mol. Med. 2001; 5(4):378-387.

Richard CP, Sidney CS C. Scott MG, James IC, Claude L. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. Journal of the American College of Cardiology. 2002;40(3):567-569.

Ward S, Lloyd M, Pandor A, Holmes M, Ara R, Ryan A, W Yeo W, Payne N. A systematic review and economic evaluation of statins for the prevention of coronary events. Healt Technology Assessment. 2007;11:3-19.

Stephanie S. Statins and Myoglobin: How muscle pain and weakness progress to heart, lung and kidney failure; 2010.
Available:[email protected]

Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80:565–81.

Mister R, Lees B, Flather M. Oestrogen and cardiovascular disease. J R Coll Physicians Edinb. 2004;34(13):4- 12.

Garvan C. Kane, James J. Lipsky. Drug–grapefruit Juice Interactions. Mayo Clin Proc. 2002;75:933-942.

SA Pharmaceutical Journal. 2008;28.
Available:http://www.drugs.com/drug-interactions/amoxicillin-clarithromycin lansoprazole-with-atorvastatin-188-0-276-0.html

Derek MF. Statin-related muscle toxicity. Clin Pharmacol. 3(10): 554- 560.

Taguchi N, et al. Prenatal exposure to HMG-CoA reductase inhibitors: Effects on fetal and neonatal outcomes Epub; 2008.

Godfrey LM, et al. Teratogenic risk of statins in pregnancy. Epub; 2012.